Nguyen Quoc-Bao D, Stender Carly, Bur Delfina, Silapunt Sirunya
Department of Dermatology, University of Texas McGovern Medical School at Houston, Houston, Texas.
Department of Dermatology, MD Anderson Cancer Center, Houston, Texas.
Dermatol Surg. 2022 Sep 1;48(9):961-966. doi: 10.1097/DSS.0000000000003520. Epub 2022 Jun 23.
Polidocanol is an FDA-approved treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, but numerous other off-label dermatological applications have been reported.
To describe the various off-label dermatological clinical uses of polidocanol, as well as efficacy and adverse effects.
The review of studies searchable on PubMed from 2004 to 2021 describing clinical uses of polidocanol to determine efficacy and adverse effects associated with various dermatologic applications.
Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. Commonly reported side effects include pain, erythema, swelling, ecchymosis, and ulceration. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls.
Although polidocanol is currently only FDA approved for incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, the use of polidocanol has been selected for a variety of off-label clinical applications.
聚多卡醇是一种经美国食品药品监督管理局（FDA）批准用于治疗大隐静脉功能不全、副隐静脉以及大隐静脉系统可见静脉曲张的药物，但也有许多其他非标签的皮肤科应用报道。
描述聚多卡醇在皮肤科的各种非标签临床应用以及疗效和不良反应。
检索2004年至2021年可在PubMed上搜索到的描述聚多卡醇临床应用的研究，以确定与各种皮肤科应用相关的疗效和不良反应。
聚多卡醇已显示出对小唾液腺黏液囊肿、血管瘤、上肢静脉、胸部网状静脉、面部静脉、化脓性肉芽肿、局限性淋巴管瘤、指黏液囊肿、混合性皮肤溃疡、皮肤局灶性黏蛋白沉积症、血清肿、静脉球瘤样畸形、痤疮囊肿、淋巴管囊肿和蜂窝织炎的治疗效果。常见的副作用包括疼痛、红斑、肿胀、瘀斑和溃疡。大多数资料来源为病例报告和小型前瞻性研究，因此支持许多应用的数据强度受到样本量小和缺乏对照的限制。
虽然聚多卡醇目前仅获FDA批准用于大隐静脉功能不全、副隐静脉以及大隐静脉系统可见静脉曲张，但聚多卡醇已被选用于多种非标签临床应用。
